CD274 and Hepatitis: PD‐1 inhibitors (e.g., Nivolumab, Pembrolizumab) were primarily associated with hepatitis and liver function abnormalities, whereas PD‐L1 inhibitors (e.g., Durvalumab, Atezolizumab) were more frequently linked to immune‐mediated liver disease and liver failure.